// App-Quantinova.ai

S4198 2015 AHA : Prevention of Progressive Worsening of Heart Failure Over Time with the Angiotensin-receptor Neprilysin Inhibitor Sacubitril/valsartan (lcz696)

Researchers

Presenter

  • Pardeep Jhund

Principal Investigators

  • Jianjian Gong

  • Milton Packer

  • Jean Rouleau

  • Martin Lefkowitz

  • Akshay Desai

  • Adel Rizkala

  • Victor Shi

  • Karl Swedberg

  • Michael Zile

  • Scott Solomon

Medical Centers

  • Brigham & Women's Hospital, Boston, MA

  • University of Montreal, Montreal, QC, Canada

  • Univ Texas Southwest Med Ctr, Dallas, TX

  • The Medical Univ of South Carolina and RHJ Dept of Veterans Admin Medical center, Charleston, SC

  • Univeristy of Gothenburg, Gothenburg, Sweden.

  • University of Glasgow, Glasgow, United Kingdom

Locations

  • United States

  • Canada

  • United Kingdom

  • Sweden

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Heart failure with reduced ejection fraction

Biomarkers

  • Neprilysin

Drug/Treatment

  • Sacubitril/valsartan

  • Angiotensin II

  • Sacubitril

  • Enalapril maleate

  • Valsartan

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved